Ocular Therapeutix (OCUL) Tops Q1 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil slides following outreach to Iran to limit Houthis actions in Red Sea
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Ocular Therapeutix™ Reports First Quarter 2022 Financial Results and Business Update
May 9, 2022 4:01 PM EDTDEXTENZA® (dexamethasone ophthalmic insert) 0.4 mg Recorded Quarterly Net Product Revenue of $12.5 Million, Representing Year-Over-Year Growth of 87%
Guiding DEXTENZA Annual Net Product Revenue for 2022 between $55 to $60 million, Representing Annual Growth of Approximately 26% to 38%
Expanding Commercial Team to Address the Commercial Opportunity for DEXTENZA in the Office Setting
Topline Data from the U.S.-based Clinical Trial for OTX-TKI for the Treatment of Wet AMD Anticipated in the Third Quarter of 2022
Dosing of Subjects in Phase 2 OTX-TIC Clinical Trial for the... More
